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Abstract 21 
The trigeminal brainstem sensory nuclear complex is the first central relay structure mediating 22 
orofacial somatosensory and nociceptive perception. Animal studies suggest a substantial 23 
involvement of neurochemical alterations at such basal CNS levels in acute and chronic pain 24 
processing.  Translating this animal based knowledge to humans is challenging. Human 25 
related examining of brainstem functions are challenged by MR related peculiarities as well as 26 
applicability aspects of experimentally standardized paradigms.  27 
Based on our experience with an MR compatible human orofacial pain model, the aims of the 28 
present study were twofold: 1) from a technical perspective, the evaluation of proton magnetic 29 
resonance spectroscopy at 3 Tesla regarding measurement accuracy of neurochemical profiles 30 
in this small brainstem nuclear complex and 2) the examination of possible neurochemical 31 
alterations induced by an experimental orofacial pain model.  32 
Data from 13 healthy volunteers aged 19 to 46 years were analyzed and revealed high quality 33 
spectra with significant reductions in total N-acetylaspartate (N-acetylaspartate + N-34 
acetylaspartylglutamate) (-3.7%, p = 0.009) and GABA (-10.88%, p = 0.041) during the pain 35 
condition. These results might reflect contributions of N-acetylaspartate and N-36 
acetylaspartylglutamate in neuronal activity-dependent physiologic processes and/or 37 
excitatory neurotransmission, whereas changes in GABA might indicate towards a reduction 38 
in tonic GABAergic functioning during nociceptive signaling.  39 
Summarized, the present study indicates the applicability of 1H-MRS to obtain neurochemical 40 
dynamics within the human trigeminal brainstem sensory nuclear complex. Further 41 
developments are needed to pave the way towards bridging important animal based 42 
knowledge with human research to understand the neurochemistry of orofacial nociception 43 
and pain.  44 
 45 
Keywords: proton magnetic resonance spectroscopy, brainstem, trigeminal brainstem sensory 46 
nuclear complex TBSNC, region-specific neurochemistry, N-acetylaspartate NAA, GABA, 47 
dental pain, orofacial pain, human pain model 48 
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Introduction 51 
Pain in general and orofacial pain in particular are complex multifaceted phenomena 52 
encompassing sensory, affective, cognitive and motor processes. Worldwide costs, suffering 53 
and psychosocial distress especially in chronic forms are immense (Maixner et al., 2011; 54 
Murray and Lopez, 2013). Related brain mechanisms have been disentangled up to a certain 55 
degree, with several (predominantly cortical) areas being involved in decoding specified 56 
information from the underlying pain cascade (Peyron et al., 2000; Wager et al., 2013; Denk 57 
et al., 2014). In contrast to these quite well described (pain related) neuronal correlates, the 58 
brainstem still remains scarcely characterized, particularly in humans (Beissner and 59 
Baudrexel, 2014).  60 
As neuronal gate to and from the cortex, this structure is involved in a multitude of vital 61 
functional processes and of crucial importance for our daily survival. The functional spectrum 62 
of this area covers co-control of breathing, sleep-wake rhythms, blood pressure, heart rate, 63 
pain modulation and even higher cognitive and psychological functions (Sessle, 2005; 64 
Fairhurst et al., 2007; Hurley et al., 2010). 65 
Listed as one of the most prevalent pain conditions, orofacial pain seems strongly associated 66 
with maladaptive brainstem processing (Sessle, 2000; Maixner et al., 2011). The collective 67 
term “orofacial pain” encompasses a variety of pain types perceived in the face, jaw and oral 68 
cavity including acute (eg. dental pain) and chronic conditions (eg. trigeminal neuralgia; 69 
trigeminal neuropathic pain; burning mouth syndrome; temporomandibular disorders) 70 
(Zakrzewska, 2013). One commonality of these different pain types is that their nociceptive 71 
information is exclusively transmitted to the brain via the trigeminal brainstem sensory 72 
nuclear complex (TBSNC) (Sessle, 2000). This intricate nuclear cluster represents the first 73 
relay station in the brain for peripheral somatosensory afferents from the trigeminal nerve 74 
(and to a smaller extent from the facial and glossopharyngeal nerves) (Sessle, 2000; DaSilva 75 
and DosSantos, 2012). It consists of three nuclei ranging from the mesencephalon down to the 76 
cervical dorsal horn, namely: mesencephalic, principal and spinal trigeminal nucleus 77 
(Nieuwenhuys et al., 2008). The spinal trigeminal nucleus (Sp5) is further subdivided into 78 
three subnuclei in a rostral to caudal fashion: Subnuclei pars oralis, pars interpolaris and pars 79 
caudalis (Dubner and Bennett, 1983; Beck et al., 1997; Nieuwenhuys et al., 2008). The 80 
TBSNC (Sp5 in particular) receives nociceptive signals from the ipsilateral site of the face 81 
and mouth via Aδ and C-fibers and forwards them via 2nd-order neurons to the contralateral 82 
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ventral posteromedial nucleus (VPM) of the thalamus from which the stimuli are further 83 
projected to several cortical structures (Nieuwenhuys et al., 2008). 84 
Based on animal studies, cellular and neurochemical alterations in the TBSNC were suggested 85 
being crucially involved in processing acute pain as well as in maladaptation mechanisms 86 
leading to pain chronification. Neurochemicals released in the TBSNC by afferents, 87 
interneurons and (pain) modulatory pathways – most notably GABA, 5-HT and opioids – 88 
alter the processing of nociceptive input on that basal CNS level (Sessle, 2000). Exemplary 89 
are various investigations demonstrating changes in GABAergic neurotransmission associated 90 
with trauma, inflammation and partial deafferentation (Sessle, 2000; Viggiano et al., 2004; 91 
Takeda et al., 2011). Additionally, evidence is given by chronic neuropathic pain models. 92 
Using a constriction injury model of the rat infraorbital branch of the trigeminal nerve (CCI-93 
ION), only baclofen (a GABAB-receptor agonist) but not carbamazepine, morphine or 94 
tricyclic antidepressants were able to reduce the allodynia-like behavior (Idänpään-Heikkilä 95 
and Guilbaud, 1999).  Using a similar model, Martin et al. (2010) found a decrease in GAD65 96 
immunoreactivity in the caudal nucleus of the Sp5 suggesting a disruption in GABA-mediated 97 
inhibitory circuits.  98 
Few human neuroimaging studies addressed the specific functional/anatomical contributions 99 
of the TBSNC in acute and chronic orofacial pain by applying functional magnetic resonance 100 
imaging (fMRI) (DaSilva et al., 2002), diffusion tensor imaging (DTI) and voxel-based 101 
morphometry (VBM) (Wilcox et al., 2015). However, none of the performed neuroimaging 102 
studies provided insights regarding neurochemical alterations in the human TBSNC thus 103 
corroborating some results provided by animal studies. But this question could be addressed 104 
by proton magnetic resonance spectroscopy (1H-MRS), a powerful method able to 105 
simultaneously quantify neurochemical compounds in a defined brain region. Typically 106 
measured neurochemicals provide for example information about neuronal density and 107 
viability (N-acetylaspartate), energy metabolism (creatine/phosphocreatine), membrane 108 
turnover and integrity (choline), antioxidant status (glutathione), glial cell proliferation (Myo-109 
inositol) or neurotransmission (Glutamate, GABA, N-acetyl-aspartyl-glutamate)(Stagg, 110 
2013). Theoretically, 1H-MRS allows observing neurochemical processes and alterations 111 
associated with acute and chronic (orofacial) pain conditions within relevant brainstem nuclei. 112 
Thus a bridge from human research to the animal studies on TBSNC might be in reach.  113 
However, in-vivo measurements on brainstem levels face a series of significant challenges as 114 
technical, structural and physiological characteristics of the brainstem and spinal cord impede 115 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
5 
 
proper MR acquisitions. Blood flow in adjacent arteries/venes and CSF pulsation in and 116 
around the brainstem induce inhomogeneity in the static magnetic field (B0) thus causing 117 
frequency shifts resulting in poor spectral resolution (Brooks et al., 2013; Beissner and 118 
Baudrexel, 2014; Hock et al., 2013). Furthermore, the signal obtained by 1H-MRS is in 119 
general very minute, demanding large measurement volumes (usually voxel sizes of 8 ml) in 120 
order to achieve sufficient signal-to-noise ratios (SNR) in a reasonable acquisition time 121 
(Kreis, 2004; de Matos et al., 2016). But, measuring the TBSNC with the adequate anatomical 122 
and functional specificity demands smaller voxel sizes and hence requires adaptations towards 123 
long acquisition times. Those, in turn enhance the likelihood for temporal changes in the B0 124 
field caused by subject motion and B0 drifts resulting in frequency and phase shifts between 125 
single free induction decays (FIDs). All these facets hamper spectral quality aspects and 126 
require careful planning and adequate measurement strategies (Hock et al., 2013c).  127 
In this feasibility study, we provide a brainstem optimized 1H-MRS sequence and data post 128 
processing scheme in combination with a reliable experimental dental pain model in healthy 129 
volunteers. The following two questions were pursued: 1) 1H-MRS measurability aspects of a 130 
small brainstem area from a technical perspective and 2) possible alterations in the 131 
neurochemical milieu induced by experimental dental pain.  132 
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Materials and Methods:  133 
The present study was conducted from March 2015 to December 2015 according to the 134 
Declaration of Helsinki and was approved by the local ethics committee.  135 
Subjects: 136 
26 healthy males (mean age: 27.35 ± 6.84, range: 19-46) were recruited for the study. 137 
Inclusion criteria required the test tooth (right upper canine) to be vital, caries free, 138 
sensorically intact and free of previous dental treatments. Exclusion criteria were psychiatric 139 
and neurologic diseases, regular pain medication intake, pain syndromes, claustrophobia and 140 
general contra-indications for MR. No female volunteers were recruited due to possible 141 
variability in pain perception caused by menstrual cycle associated variation in hormonal 142 
levels (Wiesenfeld-Hallin, 2005).  143 
All subjects received detailed information about the experimental procedure, aim of the study 144 
and provided their written informed consent before any procedure was performed. Subjects 145 
were instructed not to consume alcohol, analgesic medication and other drugs 24h before the 146 
start of the MR experiment and to be fed before participation. Participants were explicitly 147 
informed to have the possibility to terminate participation and withdraw from the study at any 148 
time. They were financially compensated (40 Swiss francs/hour) for the effective time of 149 
participation.  150 
From the initial 26 recruited participants, 8 were excluded after the test session due to 151 
insufficient and/or inconstant pain intensity perception; therefore 18 subjects were included in 152 
the study. Two subjects had to be excluded due to spectral artifacts and two others due to 153 
insufficient spectral resolution (FWHM NAA > 10Hz). An additional subject had to be 154 
excluded due to strong movements during the experimental conditions, resulting in a total of 155 
13 (mean age: 27.69 ± 7.89, range: 19-46) data sets for analysis.  156 
 157 
  158 
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Dental stimulation setup: 159 
Dental stimulation was administered to the right upper canine. For this purpose, individual 160 
dental splints with non-ferromagnetic stainless steel electrodes embedded directly at the 161 
center of labial and palatal surfaces were fabricated. To reduce electrical resistance, small 162 
portions of hydrogel (size ca. 3x3mm) covering the electrodes were applied before splint 163 
insertion.  164 
In addition to the tooth stimulating electrodes, a small 2 MΩ resistor (surface-mount device, 165 
SMD, KOA Corporation, Tokyo, Japan) was placed on the left side of the dental splint over 166 
the second left incisor tooth and sealed with Blu-Mousse (thixotropic vinyl polysiloxane; 167 
Parkell, Edgewood, USA). This resistor served as “dummy tooth” enabling running of the 168 
stimulation procedure during the baseline measurements without evoking sensory perceptions. 169 
This approach allowed for identical conditions during baseline and pain 1H-MRS 170 
measurements. 171 
For details regarding splint fabrication and stimulation equipment specs, please see Gutzeit et 172 
al., 2013. 173 
 174 
Psychophysical testing and familiarization: 175 
Subjects were invited to a test session 1-2 weeks prior to the MR-experiment. The aim of this 176 
preceding visit was fourfold: 1) Check of inclusion/exclusion criteria, 2) manufacturing of the 177 
dental splint, 3) psychophysical testing of the subjects’ sensory and pain thresholds and 4) 178 
familiarization of the participant with the dental stimulation procedure and equipment. 179 
The psychophysical testing consisted of the administration of electrical pulses of 1 ms 180 
duration with linearly increasing electrical currents and randomized inter-stimulus-intervals 181 
(ISI) 5-8s long. The procedure started at an imperceptible intensity of 1 mA; the intensity was 182 
then increased in steps of 1 mA. Thresholds for sensory detection (SDT), pain detection 183 
(PDT), and a stimulus intensity corresponding to the subjects’ individual rating of 4-5 184 
(moderately painful) on a NRS were obtained. 4-5 was the target pain intensity for the pain 185 
stimulation condition in the MR-experiment. Subjects indicated the SDT, PDT and 4-5 by 186 
hand signs. This procedure was repeated 3 times to assure the stability of individual sensory 187 
thresholds as well as account for novelty effects and potential initial feelings of uneasiness 188 
associated with the dental stimulation.  189 
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Experimental Procedure:  190 
At the beginning of the MR-experiment, psychophysical testing (procedure identical to the 191 
test session) was performed and the SDT, PDT and intensity of 4-5 was evaluated outside the 192 
scanner to test the participants’ current perceptual characteristics. 193 
The subjects were then positioned in the 3-Tesla MR unit (Philips Healthcare, Best, The 194 
Netherlands) in a supine position. Since small voxel dimensions were applied in an 195 
anatomical localization difficult to investigate, it was crucial to keep head movements at a 196 
minimum. Multipad positioning cushions (Pearltec AG, Schlieren / Zurich, Switzerland) were 197 
used for this purpose. Two were bilaterally placed between the temple and the coil, and a third 198 
was positioned under the participant’s neck/occipital head. Subjects adjusted the cushion 199 
 
 
Figure 1: Panels A-C illustrate the MRS voxel placement on sagittal (A), coronal (B) and transversal 
(C) anatomical images. Orange and white boxes represent the acquisition volumes of lactate (orange) 
and myo-inositol (white) which are shifted relative to each other due to the chemical shift artifact. This 
artifact is reduced by the use of inner-volume saturation (IVS) bands. The red box corresponds to the 
resulting excitation volume generating the MRS signal. In addition, the shim box is represented by the 
green box. Panels D-F illustrate the position of the excitation volume (red) in relation to the 
schematically represented TBSNC with the associated mesencephalic (dark green), primary (light 
green) and spinal trigeminal nuclei (blue) on sagittal, coronal and transversal images.  
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inflation for optimal comfort which is essential considering the extended measurement 200 
durations. Participants were instructed to press the alarm button in case of discomfort caused 201 
by the head fixation system.  202 
After acquisition of anatomical sequences and placement of the MRS-voxel, the baseline 203 
MRS measurement was obtained. During this baseline condition, dummy stimulation was 204 
applied. Psychophysical testing was then repeated inside the scanner to adjust, if necessary, 205 
the electrical current strength evoking a 4-5/10 pain intensity. Prior to the painful 206 
measurement sequence, correct voxel placement was verified on another set of anatomical 207 
images and adjusted if necessary. Electrical stimulation during the baseline and pain 208 
stimulation block consisted of 128 short pulses (1 ms, identical characteristics as during the 209 
psychophysical testing) administered with an ISI of 10-12.5s (block duration: approx. 21 210 
 
 
Figure 2: Exemplary spectrum fitted with LCModel. The fitted spectum (red) is superimposed on the 
raw spectrum (grey). The difference of raw and fitted spectrum is displayed by the residuum which is 
an indicator for the goodness-of-fit. The spectral baseline is delineated by the dashed grey line. The 
fits of the reported neurochemicals are displayed below the baseline. 
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minutes). Previous work demonstrates that the applied dental stimulation paradigm is not 211 
prone to sensitization and habituation effects during long measurement periods (Brügger et 212 
al., 2012). The total duration of the MR measurement was approx. 60 min.  213 
 
Figure 3: Overview of the spectral quality range of included spectra. Quality estimates (from 
LCModel) of the best spectrum (A) were: SNR = 23, Linewidth = 4.85 Hz. Estimates of the worst (B) 
were: SNR = 12, Linewidth = 7.79 Hz. Mean spectral quality over all spectra: SNR = 19.08, 
Linewidth = 6.41 Hz. Panels C and D illustrate the spectral variability as overlay of all 13 included 
spectra (colored lines) with the corresponding averaged spectrum (black) for the baseline (C) and pain 
(D) condition. 
 
0.511.522.533.54 0.511.522.533.54
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 214 
MR protocol 215 
The integrated body coil was used for transmission (maximum B1 = 13.5 µT); a receive-only 216 
8 channel head coil array (Philips Healthcare, Best, NL) was applied for signal reception. 217 
Anatomical high-resolution T2-weighted turbo spin-echo sequences were performed in axial 218 
and sagittal orientations (TR/TE = 3000/120; Flip-angle = 90°; voxel size 0.8x1x3.2mm3) to 219 
ensure precise voxel planning and positioning. 220 
For the MR spectra acquisition, an inner-volume saturated (IVS)(Edden et al., 2006; Hock et 221 
al., 2013), non-water suppressed PRESS (point-resolved spectroscopy) sequence (TR/TE = 222 
2500/32 ms; data points = 1024; sample frequency = 2000 Hz; readout duration = 512 ms; 223 
number of averages = 512) was used via the metabolite cycling (MC) technique (MC-PRESS) 224 
(Dreher and Leibfritz, 2005; Hock et al., 2013). This  enables a simultaneous recording of 225 
water and neurochemical signals, by adding or subtracting consecutively acquired echoes 226 
modulated via alternate up- or downfield inversion pulses which do not affect the water signal 227 
(Dreher and Leibfritz, 2005; Hock et al., 2013). Therefore, MC-PRESS allows the acquisition 228 
of high SNR water-peaks from single FIDs, permitting frequency alignment, phase and eddy 229 
current correction before averaging of neurochemical spectra. Hence, MC-PRESS provides 230 
the potential to reduce frequency shifts caused by pulsatile effects of blood vessels/CSF and 231 
B0 drifts. Furthermore, the simultaneous acquisition of both water and neurochemical signals 232 
means that both are subject to the same MR-specific and physiologic influences thus 233 
optimizing the use of the water peak as an internal reference during neurochemical 234 
quantification.  235 
To optimally cover the region of interest, the MRS voxel was carefully placed along the 236 
transition zone to the 4th ventricle. Important to note: due to individual shapes and contours 237 
of the volunteers’ brainstem, the placements were adjusted to avoid contamination of the 238 
MRS voxel with CSF from the 4th ventricle, central canal and cisterna magna. The voxel was 239 
placed on the ipsilateral side in reference to the stimulated tooth using following dimensions: 240 
37.6 x 8.5 x 7.6 mm (2.4ml, Fig. 1).  241 
 242 
MRS data post processing 243 
MRS data were post-processed according to Hock et al. (2013; 2016). The individual 512 244 
FIDs were truncated after 100ms and zero-filled to 1024 points, followed by frequency 245 
alignment, phase and eddy current correction of individual FIDs before averaging. These 246 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
12 
 
steps were performed using in-house scripts running on MATLAB 2013b (MathWorks, 247 
Natick, MA, USA).  248 
In case of a significant mismatch of spectral linewidth estimates between both conditions, 249 
filtering by means of an exponential multiplication was performed to minimize systematic 250 
errors in neurochemical quantification. This approach prevents false neurochemical 251 
differences between the conditions (Mangia et al., 2007). The correction was done by 252 
matching the water peak linewidth to the water peak linewidth of the pain spectrum. 253 
Individual filter parameters were chosen to ensure the best match possible for each 254 
participant.  255 
 256 
Quantification of Neurochemicals 257 
 Neurochemicals were quantified with LCModel (Provencher, 1993) using a set of basis 258 
spectra which were simulated using the GAMMA Simulation Package (Smith et al., 1994). 259 
The basis set included the following components: N-acetyl aspartate (NAA), N-acetyl-aspartyl 260 
glutamate (NAAG), glycerophosphocholine (GPC), phosphocholine (PCh), creatine (Cre), 261 
myo-Inositol (mI), glycine (gly), alanine (Ala), ascorbic acid (Asc), aspartate (Asp), 262 
ethanolamine and phosphorylethanolamine (PE), glutamine (Gln), glutamate (Glu),  263 
glutathione (GSH), glucose (Glc), γ-aminobutyric acid (GABA), lactate (Lac), taurine (Tau) 264 
and scyllo-inositol (sI). The chemical shift range was set to 4.0-0.5 ppm. Following 265 
neurochemicals with strongly overlapping spectra were combined to one single spectrum: Glu 266 
+ Gln = Glx, GPC + PCh = tCho, mI + Gly = tmI and NAA + NAAG = tNAA.  267 
With respect to neurochemical related inclusion criteria, we followed the suggestions 268 
provided by De Graaf (2007): Neurochemicals with CRLB<10% count as measured with 269 
sufficient precision, neurochemicals with CRLB <20-30% should be considered with caution 270 
whereas neurochemicals with CRLB >30% are deemed unreliable and should therefore be 271 
excluded from the analysis. Hence, the following neurochemicals were included: tNAA, tCho, 272 
tmI, Cre, Glx, GSH, Scyllo and GABA. 273 
We decided to use water (from the simultaneously acquired water spectra) as internal 274 
reference instead of Cre due to the following reasons: 275 
1. Previous pain MRS studies observed significant alterations in Cre concentrations (see 276 
Gutzeit et al., 2013). 277 
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2. Reduced sensitivity due to combined quantification errors of Cre and the other 278 
neurochemicals (resulting in higher variation). 279 
3. Unspecific Cre signal changes could either under- or overestimate "true" effects in other 280 
neurochemicals evoked by the experimental conditions.  281 
 282 
Movement  283 
Two navigator sequences were performed during both conditions. This procedure enables two 284 
different approaches to reduce the impact of motion on the neurochemical data: Firstly, real 285 
time feedback to instruct the volunteers not to move and secondly, rejecting data sets with 286 
excessive levels of motion.  287 
Navigator sequences were carried out in the dead time before the inner-volume saturation 288 
(IVS) pulses of each single MRS acquisition (pencil-beam excitation with radius r = 30mm 289 
and length l = 100mm; flip-angle = 15°, acquisition duration = 2.9ms) (Hock and Henning, 290 
2016).  291 
The first navigator (Nav I, anterior-posterior axis) was positioned ventral to the MRS voxel 292 
perpendicularly oriented to the medulla. The second one (Nav II, left-right axis) was placed 293 
dorsally to the MRS-voxel covering corpus callosum and occipital areas (Fig. 4).   294 
 
Figure 4: Placement of the two navigators (orange) shown on sagittal (A) and coronal (B) images. , 
The lower navigator (Nav I) measured movement in the anterior-posterior axis, he upper navigator 
(Nav II) measured movement in the left-right axis. The red box corresponds to the MRS excitation 
volume.  
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Navigator positions were extracted from the raw MR data using MRecon (GyroTools, Zurich, 295 
Switzerland). The extracted movement data was used for the calculation of relative movement 296 
during individual scans using the first navigator acquisition as reference. A gating window of 297 
±1mm was used to identify echoes associated with significant movement. Navigator data 298 
demonstrating excessive noise were excluded (See excluded data sets in supplementary 299 
material).  300 
Spectra from individual participants were excluded from the analysis based on their 301 
movement estimates if more than 10% of the individual spectral acquisitions were shifted 302 
outside the gating window. 303 
 304 
 Statistical analysis 305 
 SPSS 22 (IBM Corp., Armonk, NY, USA) was used to perform the statistics; the significance 306 
threshold was set at p < 0.05. First, data were tested for normal distribution by means of the 307 
Shapiro-Wilk test. Differences between both experimental conditions regarding 308 
neurochemical concentrations were tested using a paired t-test, whereas comparison of SNR 309 
Table 1: Estimates of spectral quality and fitting errors (CRLB) of the included spectra from the baseline and 
pain conditions. In addition, inter-scan variation estimates are presented as coefficients of variation (CV). 
Values are reported as means ± SD. 
        
  Baseline Pain P 
        
Spectral quality:       
        
FWHMNAA[Hz] a 6.6 ± 1.7 5.8 ± 1.6 0.008 
FWHMNAA[Hz] b 6.5 ± 1.6 6.3 ± 1.4 0.611 
 
SNRNAA 19.1 ± 2.7 19.1 ± 2.3 1.000 
        
 
CRLB [%]:     Inter-scan CV [%]: 
        
tCho 3.2 ± 0.7 3.0 ± 0.6 2.7 ± 1.6 
tNAA 2.8 ± 0.4 3.2 ± 0.8 3.4 ±2.1 
tmI 3.4 ± 0.5 3.3 ± 0.5 2.4 ± 2.3 
Cre 3.4 ± 1.1 3.3 ± 0.5 2.6 ± 2.0 
Glx 9.3 ± 1.7 11.0 ± 5.2 12.6 ± 12.7 
Scyllo 18.6 ± 7.4 19.3 ± 7.3 13.72 ± 10.6 
GSH 21.9 ± 7.8 23.8 ± 11.3 25.3 ± 26.5 
GABA 23.4 ± 6.3 26.5 ± 8.4 16.1 ± 15.9 
        
a
 Linewidth estimates provided by LCModel without  linewidth-matching of the water peaks 
b
 Linewidth estimates provided by LCModel with  linewidth-matching of the water peaks (by 
means of exponential  filtering) 
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and linewidth was tested using a Wilcoxon signed-rank. In order to estimate reproducibility, 310 
inter-scan variability (variability between baseline and pain condition for each participant)  311 
was estimated by means of coefficient of variation (CV, calculated as SD/Mean*100). 312 
 313 
Results 314 
Data quality 315 
Mean spectral quality and fitting error estimates for both conditions are shown in table 1. 316 
Linewidth estimates provided by LCModel differed significantly between both conditions (Z 317 
= -2.670, p = 0.008). In order to minimize linewidth differences, individual baseline spectra 318 
were filtered resulting in negligible linewidth differences (Z = -0.509, p = 0.611). 319 
Mean SNR was 19.1 for both conditions and thus not significant (Z = 0.000, p = 1.000). 320 
The good data quality is also reflected by the low CRLB over all spectra and all subjects 321 
(Baseline: 9.6%; Pain: 11.1%). As a consequence, resulting inter-scan CV were low with 322 
mean CV of 9.85% over all participants and included neurochemicals (see Table 1).  323 
 324 
 325 
 326 
Table 2: Water peak area (mean ± SD; area under the curve, AUC) and absolute neurochemical 
concentrations (mean ± SD; institutional units) of included metabolites from both conditions. Significance 
levels of the paired t-test between both conditions are represented under p. 
 
Baseline Pain Abs. Change Rel. Change [%] p 
H2OAUC 47.48 ± 4.75 47.58 ± 4.39 0.10 ± 0.61  0.29 ± 1.52 0.580 
            
tCho 6.50 ± 0.75 6.44 ± 0.75 -0.06 ± 0.30 -0.78 ± 4.50 0.515 
tNAA 22.89 ± 2.54 22.01 ± 2.35 -0.87 ± 1.01 -3.70 ± 4.11 0.009 
tmI 21.73 ± 2.70 21.55 ± 2.25 -0.18±1.05 -0.50 ± 4.73 0.552 
Cre 15.31 ± 1.56 15.13 ± 1.56 -0.18 ± 0.74 -1.07±4.51 0.404 
Glx 19.28 ±4.09 18.17 ± 5.55 -1.10 ± 3.81 -3.67 ± 25.35 0.317 
Scyllo 1.28 ± 0.44 1.18 ± 0.41 -0.10 ± 0.26 -3.93 ± 22.73 0.206 
GSH 3.57 ± 1.33 3.35 ± 1.42 -0.23 ± 1.57 2.02 ± 44.85 0.612 
GABA 6.29 ± 1.79 5.40 ± 1.63 -0.89 ± 1.41 -10.88 ± 24.47 0.041 
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Movement 327 
Two movement datasets from navigator 2 had to be excluded due to excessive noise, resulting 328 
in a complete data set of 13 movement profiles for navigator 1 (anterior-posterior, AP) and 11 329 
movement profiles for navigator 2 (left-right, LR; Illustrations of the individual movement 330 
profiles are provided in the supplementary material). Spectra from one participant had to be 331 
excluded due to a significant drift movement in the anterior-posterior direction.  332 
The movement quantification results are summarized in table 3. The overall movement was 333 
negligible with mean displacements of -0.22 mm (AP) and -0.25 (LR). Accordingly, the 334 
percentages of navigator echoes exceeding displacements of ±1mm were minute with mean 335 
percentages of 0.70% (AP) axis and 0.81% (LR). No significant differences were observed in 336 
mean displacement magnitudes between baseline and pain conditions for Nav I (Z = 0.52, p = 337 
0.60) and Nav II (Z = 0.80, p = 0.42). In the same vein, the count of single navigator echoes 338 
lying outside gating window were also not significant between the baseline and pain condition 339 
for both navigators (Nav I: Z = -0.60, p = 0.55; Nav II: Z = 0.00, p = 1.00).  340 
 341 
Neurochemical concentrations: 342 
 Table 2 shows absolute neurochemical concentrations and the resulting changes with 343 
corresponding paired t-test results. Figure 2 graphically illustrates the intra-individual 344 
neurochemical differences as boxplots. tNAA and GABA revealed significant alterations  345 
Table 3: Movement analysis results. Mean displacement (±SD), and the mean percentage of MRS acquisitions 
(Range) exceeding the gating-window (±1mm). Significance levels of the wilcoxon-test between both 
conditions are represented under p. 
              
  
Group analysis Nav I (anterior-posterior axis)   Nav II (left-right axis) 
  
Baseline Pain p 
 
Baseline Pain p 
Mean  [mm] -0.19 ±0.25 -0.25 ± 0.22 0.60   -0.27 ± 0.28 -0.23 ± 0.26 0.42 
Echoes > ±1mm [%] 0.50 (0-3.13) 0.90 (0-7.81) 0.55   0.57 (0-4.30) 1.05 (0-9.57) 1.00 
  
            
  
              
  
Excluded Participant Nav I   Nav II 
  Baseline Pain 
  
Baseline Pain 
 
Mean[mm] -0.41 -1.50     -0.07 -0.19   
Echoes > ±1mm [%] 0.00 73.83     0.00 0.00   
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during the pain condition. tNAA showed the most significant differences with a consistent 346 
drop during pain (T = 3.130(12); p = 0.009). Also GABA demonstrated a significant 347 
concentration drop during pain (T = 2.286(12); p = 0.041).  348 
 349 
 350 
Discussion 351 
In the present study, neurochemical changes within the human TBSNC during experimental 352 
orofacial pain were assessed by brainstem-optimized functional 1H-MRS. To our knowledge, 353 
this is the first human study which quantified neurochemical alterations at anatomically 354 
distinct brainstem level in response to experimental nociception. The combination of MC-355 
PRESS 1H-MRS-sequences and dedicated spectral post-processing enabled the acquisition of 356 
high quality spectra in spite of the present technical challenges inherent to the brainstem, long 357 
measurement times and small voxel dimensions. Eight neurochemicals were quantified with 358 
good reproducibility as indicated by overall low CRLBs and inter-scan CV (Table 1).  359 
From these eight neurochemicals, significant decreases were observed for tNAA and GABA 360 
during the pain application. 361 
 362 
Mechanisms underlying NAA and NAAG decreases with an emphasis on nociception 363 
 
Figure 5: Boxplots of the percent changes in neurochemical concentrations between baseline and 
pain condition. tNAA and GABA showed a statistically significant reduction during pain stimulation. 
*p<0.05; **p<0.01 
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NAA is one of the most abundant neurochemicals in the human nervous system reaching high 364 
concentrations of approx. 10mM (Moffett et al., 2007). In 1H-MRS, this neurochemical is 365 
typically represented by the highest peak in the spectrum which originates from three nearly 366 
equivalent methyl hydrogen atoms on the acetate group resonating with a frequency shift of 367 
2.02 ppm relative to the MRS standard tetramethylsilane (De Graaf, 2007). NAA is specific to 368 
neurons, being predominantly synthesized in neuronal mitochondria from aspartate and 369 
acetyl-coenzyme A by the enzyme L-aspartate N-acetyltransferase (Asp-NAT) (Stagg, 2013). 370 
NAA synthesis has been shown to be coupled to oxygen consumption and adenosine 371 
triphosphate (ATP) production, thus linking NAA to mitochondrial activity and associated 372 
neuronal energy metabolism (Benarroch, 2008).  NAA counts as a reliable marker of neuronal 373 
health and integrity (Rae, 2014).  Pursuant to, a variety of clinical conditions demonstrate 374 
transient or permanent decreases, confirmed in stroke, Alzheimer’s disease, epilepsy, brain 375 
tumors, multiple sclerosis, schizophrenia, chronic low back and orofacial pain  (Moffett et al., 376 
2007; Benarroch, 2008; Gussew et al., 2011; Gustin et al., 2011). These results point towards 377 
an indubitably important role of NAA in those pathological conditions. However, it should be 378 
emphasized that its utility as marker for general neuronal health is primarily based on 379 
empirical evidence and not on a profound understanding of its specific neuronal functions, in 380 
particular during neuronal activity (Moffett et al., 2007; Stagg, 2013; Rae, 2014). 381 
A variety of functional roles of NAA have been suggested in animal and human research. 382 
Baslow and coworkers (Baslow, 2002; Baslow et al., 2007; Baslow et al., 2016) proposed that 383 
NAA might additionally function as molecular water pump (MWP), able of removing excess 384 
water produced by increased glucose respiration during neuronal activation. According to this 385 
hypothesis, NAA is actively transported to the extracellular space in conjuction with bound 386 
water molecules. Subsequently, NAA is catabolized by aspartoacyclase (ASPA) in 387 
oligodendrocytes, releasing the bound water molecules and thus allowing water removal from 388 
the extracellular space by astrocytes. Although intriguing, the MWP-theory remains 389 
hypothetical as to date no key transport protein has been identified. Another possible 390 
mechanism for a controlled release of NAA during neuronal activation has been suggested by 391 
experiments performed on organotypic hippocampal slices. Tranberg et al. (2004) observed a 392 
NAA release during a 20 min period after a transient 5 min activation of NMDA-receptors. 393 
Importantly, the NAA efflux was not due to potassium depolarization, but to a NMDA-394 
mediated influx of Ca2+.  395 
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Such NMDA-mediated releases of NAA could function as an activity-driven mechanism for 396 
metabolic water removal thus supporting neurophysiological processes proposed by Baslow et 397 
al. (Baslow, 2002). In addition, this NMDA-mediated release could constitute a regulation 398 
mechanism for axon-glial signaling, which has been proposed by others (Moffett et al., 2007). 399 
Widely accepted is the role of NAA as precursor for N-acetylaspartylglutamate (NAAG), the 400 
highest concentrated neuropeptide in the human CNS (Benarroch, 2008). NAAG is 401 
synthesized in neurons from NAA and glutamate and is then synaptically (calcium mediated) 402 
released. NAAG is predominately converted by glutamate carboxypeptidase II (GCPII) 403 
located on the surface of astrocytes. GPCII hydrolyzes NAAG back to NAA and glutamate 404 
which are taken up by astrocytes. Glutamate is then converted to glutamine and transported 405 
back to neurons. NAA, however, is most likely released to the blood stream by astrocytes 406 
(Moffett et al., 2007).  407 
It has been suggested that NAAG binds to the metabotropic glutamate receptor 3 (mGluR3) 408 
located on presynaptic endings thus enabling a modulation of neurotransmitter release (Zhao 409 
et al., 2001; Zhong et al., 2006). Due to the co-localization of NAAG with major 410 
neurotransmitters (including glutamate, GABA, acetylcholine and serotonin, dopamine and 411 
norepinephrine), it possibly modulates their release from synapses (Moffett et al., 2007). It 412 
has been further proposed that NAAG could function as modulatory pro-transmitter. In this 413 
view, NAAG would act as a glutamate carrier, releasing glutamate at sites where active 414 
GCPII enzymes are present, therefore promoting focal glutamatergic neurotransmission 415 
(Stagg, 2013).  416 
Functional 1H-MRS (fMRS) studies have been conducted in the past to investigate 417 
neurochemical dynamics of acute experimental pain processing in cortical regions 418 
(anterior/posterior insular cortex, pregenual anterior cingulate cortex) of healthy volunteers 419 
(Mullins et al., 2005; Kupers et al., 2009; Gussew et al., 2010; Gutzeit et al., 2011; Gutzeit et 420 
al., 2013). Indeed, none of the performed studies reported significant changes in tNAA. Most 421 
interestingly, Gutzeit et al. (2011, 2013) applied the identical stimulation paradigm to 422 
investigate acute dental pain processing in the insular cortex and neither observed significant 423 
alteration regarding tNAA.  424 
What could be possible reasons for the discrepancy between the presented work and previous 425 
fMRS pain studies? On one hand, the TBSNC represents the first CNS relay area, processing 426 
"pure" somatosensory input, thus reflecting basic nociception in contrast to multifaceted 427 
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"pain" processing in cortical regions. And with respect to brainstem neurochemical 428 
characteristics and compositions, various features are evident compared to cortical regions, 429 
especially regarding NAA and NAAG. Based on animal studies it has been stated that Asp-430 
NAT enzyme activity increases from rostral to caudal brain structures with brainstem and 431 
spinal cord exhibiting the highest activity levels (Truckenmiller et al., 1985; Moffett et al., 432 
2007). Interestingly, the expression of NAAG has been suggested to follow an analogue 433 
rostral-to-caudal pattern, being present at highest concentrations in the brainstem and spinal 434 
cord (Moffett and Namboodiri, 2006; Lodder-Gadaczek et al., 2011). Considering the reports 435 
on the absence of a similar concentration gradient of NAA (Tallan, 1957; Miyake et al., 436 
1981), the elevated levels of NAAG may be linked to higher NAA synthesis rates in 437 
brainstem structures. In parallel to high NAAG concentrations, high densities of GCPII 438 
enzymes and mGluR2/3 were documented for the Sp5 in animal immunocytochemistry 439 
studies (Slusher et al., 1992; Tang et al., 2001), both closely interacting with NAAG  (Zhao et 440 
al., 2001; Zhong et al., 2006). Under the consideration of suggested interactions between 441 
GCPII and neuropathic pain (Zhang et al., 2002; Zhang et al., 2006; Yamada et al., 2012) and 442 
mGlu2/3 receptors involved in orofacial pain at brainstem levels (Tang et al., 2001), our 443 
results provide evidence regarding NAAG release and catabolism in acute nociceptive pain 444 
processing in the human TBSNC. 445 
Altogether, the observed tNAA reduction during the pain condition may reflect enhanced 446 
nociceptive-related NAAG neurotransmission in the TBSNC. The released NAAG would be 447 
degraded by GCPII releasing glutamate and NAA. The subsequent removal of NAA would 448 
finally result in a reduction of NAA signals in the spectrum. Hence, such a nociception/pain 449 
associated involvement of NAAG in the TBSNC could result in the observed reductions of 450 
tNAA. Furthermore, as NMDA likely plays a major role in nociceptive processing within the 451 
TBSNC (Sessle, 2000), activated NMDA receptors (either by direct glutamate release or 452 
indirect via NAAG) possibly lead to NAA efflux, thus further reducing the observable amount 453 
of NAA in the MRS signal.  454 
 455 
Mechanisms underlying GABA decreases with an emphasis on nociception 456 
GABA has two main roles within the CNS: On one side, it acts as neuronal metabolite 457 
throughout the cytoplasm and reflects the largest pool of GABA (Stagg, 2013). On the other 458 
hand, it is best known as main inhibitory neurotransmitter in the CNS (Stagg et al., 2011a). It 459 
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binds to two main types of receptors, both widely distributed over the brain, namely the 460 
ionotropic receptors GABAA and metabotropic GABAB. They are located pre/post and 461 
extrasynaptically, hence underlying its comprising role to extensively alter neural activation 462 
(Rae, 2014). GABA is thus involved in the modulation of a variety of physiological processes 463 
(motor control, pain, sleep) and is supposed to be dysfunctional in several pathological 464 
conditions (epilepsy, anxiety, wake-sleep disturbances, schizophrenia) as well as 465 
developmental and neurodegenerative disorders (Rae, 2014). 466 
However, to describe distinct roles of GABA within this functional diversity is challenging.  467 
Exemplary is the study of Jasmin et al. (2003). By selectively modulating GABAergic 468 
mechanisms within a distinct posterior insula subarea of freely moving rats, they evoked 469 
either analgesia by general GABAergic mediated down regulation via brainstem areas or 470 
hyperalgesia by specific GABAB receptor mediated amygdala projections. In this vein, further 471 
evidence is given by studies examining the link between animal (chronic) orofacial pain 472 
models and GABA alterations in the TBSNC, indicating generally reduced GABA levels 473 
within these pathological conditions (Idänpään-Heikkilä and Guilbaud, 1999, Sessle, 2000; 474 
Takemura et al., 2001; Viggiano et al., 2004; Martin et al., 2010; Takeda et al., 2011). Also, a 475 
recent animal study by François et al. (2017) proposed a crucial role of GABAergic neurons, 476 
however, within the rostral ventromedial medulla (RVM) in integrating sensory inputs 477 
together with internal state information, which finally leads to a gatekeeper function for 478 
mechanically evoked pain. They further suggest "that multiple parallel GABAergic systems 479 
may exist for independent descending control of distinct somatosensory modalities". 480 
In addition to evidence provided by animal research, human resting-state and functional 1H-481 
MRS studies suggest GABA involvement in clinical and acute experimental pain conditions. 482 
Henderson et al. (2013) examined GABA resting-state concentrations in the thalamus of 483 
patients with painful trigeminal neuropathy (PTN, a form of chronic orofacial pain) compared 484 
to healthy volunteers and found significant GABA decreases in patients only. Additionally, 485 
they measured volumetric gray matter reductions in the thalamus of PTN patients but not in 486 
controls. In our opinion, a conclusive interpretation of their findings as either chronic pain 487 
related down-regulated GABAergic neurotransmission or neuronal loss including GABAergic 488 
neurons is challenging and needs further investigation. More closely related to our study is the 489 
experiment performed by Cleve et al. (2015). Experimental thermal pain was administered to 490 
healthy volunteers and GABA alterations in the anterior cingulate and occipital cortex were 491 
quantified. In accordance with our results, they observed a GABA associated significant mean 492 
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drop of 15.1% during pain stimulation (we observed a drop of 10.88%). They argued that the 493 
observed drops could reflect a down-regulation of inhibitory neurotransmission associated 494 
with neuro-regulatory processes. Opposed to Cleve et al. and to the study presented here, 495 
Kupers et al. (2009) compared neurochemical alterations in the pregenual anterior cingulate 496 
cortex associated with tonic heat stimulation and found increases in GABA concentration. A 497 
reason for this discrepancy could be rooted in the different regions examined as well as the 498 
variety of MRS-sequences applied. Likely most important are differences in the type of pain 499 
stimulus and application site used: As we and Cleve et al. (2015) applied a repetitive short 500 
phasic stimulus, Kupers et al. utilized tonic heat lasting throughout the whole MRS 501 
measurement. It is highly probable that different neurochemical pain processing dynamics are 502 
engaged in the measured regions, especially considering the functional diversity of brainstem 503 
compared to insular/cingulate/frontal areas. 504 
Despite robust evidence provided for GABA involvement in neurophysiologic and pathologic 505 
pain processing (derived from animal and human studies), the question still remains about 506 
which underlying neuronal processes may have given rise to the observed reduction in GABA 507 
in our study. First of all, the GABA-signal obtained by means of 1H-MRS reflects all GABA 508 
in a defined voxel. Therefore, it is not possible to directly ascribe our observed concentration 509 
changes to specific GABA pools such as metabolic, vesicular and extrasynaptic compartments 510 
(GABA distributed in the extracellular fluid) (Stagg et al., 2011a). Also considerable is the 511 
fact that some of the pools are more tightly bound to macromolecules, thus reducing their 512 
contribution to the acquired GABA-signal (Stagg et al., 2011a). Animal 1H-MRS studies 513 
further suggest that the GABA-signal predominately reflects extrasynaptic GABA (which 514 
binds to extrasynaptic GABAA receptors) and therefore determines a general non-synaptic 515 
GABAergic tone (Stagg et al., 2011b). It is also important to mention that levels of measured 516 
GABA are not simplistically linked to excitatory activity and that an increase in GABA 517 
concentration does not necessarily correspond to increased neuronal inhibition (Rae, 2014). It 518 
has generally been proposed that overall GABA levels rather reflect a gross GABAergic tone 519 
instead of specific inhibitory activity per se. In that vein, the GABA reduction observed in our 520 
study does not need to directly mirror increases in excitatory neurotransmission within the 521 
TBSNC due to nociceptive processing (coupled with glutamatergic excitatory 522 
neurotransmission). The applied dental stimuli were of 1 ms duration giving rise to associated 523 
short dental pain perceptions. In case of induced GABAergic neurotransmission, potentially 524 
released GABA into the synaptic cleft would probably be quickly taken up by astrocytes and 525 
neurons due to the short stimulation applied. Considering the timespan between excitation of 526 
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the MRS volume until the end of the signal readout of approx. 572 ms, it is rather unlikely 527 
that such short neurotransmittory processes are measurable with the applied 1H-MRS 528 
sequence. In this view, the presented results correspond to the view that the observed decrease 529 
in GABA levels may reflect changes in a general GABAergic tone rather than specific and 530 
direct GABAergic neurotransmission.  531 
 532 
Limitations:  533 
Several limitations need to be considered. Starting with the voxel placement, measuring the 534 
TBSNC with ideal anatomical and functional specificity proved to be highly demanding. This 535 
circumstance is attributable to the shape of the TBSNC and brainstem in general impeding 536 
measurability accuracy using the available cuboid voxel shape. Higher anatomical specificity 537 
might be attainable by applying other specificity enhancement strategies currently under 538 
development and partly applicable, like the use of arbitrary voxel shapes. This technique 539 
enables an exact drawing of the region of interest according to its structural contours thus 540 
theoretically achieving higher levels of spatial selectivity (Weber-Fahr et al., 2009; Snyder et 541 
al., 2012). However, the lack of contrast of structural MRI in the brainstem hampers the visual 542 
identification of TBSNC structures. This circumstance further aggravates the achievement of 543 
optimal specificity and resulting increase of sensitivity to neurochemical processes in the 544 
TBSNC.  545 
The exclusive assessment of the neurochemical milieu of the TBSNC ipsilateral to the 546 
stimulated tooth could represent a further limitation. An additional measurement of the 547 
contralateral TBSNC in rest and during dental stimulation could provide valuable insights 548 
regarding the lateralization specificity of the observed neurochemical alterations. In the same 549 
vein, an additional recovery phase after the pain condition could provide further information 550 
on the dynamics of the recorded neurochemical effects. Such examinations are planned. 551 
A possible limitation could be rooted in the exclusive participation of healthy male 552 
volunteers. The testing of a female population may demand an adaptation of voxel dimensions 553 
due to different brain sizes thus impeding a generalization of our results to the female 554 
population and further studies might be necessary.  555 
Further on, we would like to comprehensively address possible limitations regarding the 556 
observed changes in GABA.  557 
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At 3 Tesla, detection and quantification of GABA is challenging as the signal significantly 558 
overlaps with resonances from other neurochemicals. Several approaches have been 559 
developed to improve the quantification of GABA at this field strength (Mescher et al., 1998; 560 
Schulte and Boesiger, 2006; Stagg, 2013). The most commonly and widely accepted gold-561 
standard of GABA quantification at 3 Tesla is a spectral editing technique named MEGA-562 
PRESS. This method allows the separation of the 4CH2-GABA multiplet from the overlapping 563 
resonances (Mescher et al., 1998). MEGA-PRESS is a two-step approach which requires the 564 
acquisition of “on and off” spectra to calculate the edited spectrum. To date, with respect to 565 
our paradigm and the neurochemical quantification within the TBSNC, this method is not 566 
applicable due to required voxels sizes and measurement time (high volunteer stress).  567 
Another technique able to improve GABA quantification is 2D J-resolved MRS in 568 
combination with two-dimensional fitting procedures (Schulte and Boesiger, 2006; Stagg, 569 
2013). However, this approach is also limited within the frame of the present study as 570 
significantly larger voxel sizes and longer scan times are required to achieve sufficient SNR.   571 
In this report, MRS sequences and post-processing techniques are based on spinal cord MRS 572 
Hock et al., 2013; Hock et al., 2013a; Hock et al., 2016) and are optimized for quantification 573 
of neurochemical profiles in the TBSNC. Although methodological work suggests that 574 
unedited short-TE MRS measurements at 3 Tesla can yield relatively reliable GABA 575 
quantification, distinct caution must be applied regarding the spectral quality between 576 
conditions, as differences in linewidth and SNR systematically bias GABA quantification and 577 
fitting error estimates (Near et al., 2013). In that sense, special care was applied to ensure 578 
comparable spectral quality estimates (linewidth and SNR) between the baseline and pain 579 
condition, hence minimizing systematic quantification biases between both conditions 580 
(reported in table 1). Another consequence of the resonance overlaps from GABA and other 581 
neurochemicals are increased GABA fitting errors. As rule of thumb, neurochemicals 582 
determined with CRLB < 20-30% are not considered unreliable, but should be interpreted 583 
with caution (De Graaf, 2007). Although mean CRLB for GABA in both conditions meet this 584 
criterion, it is important to emphasize that CRLB only reflect lower bounds and therefore may 585 
underestimate the actual magnitude of fitting errors. To overcome mentioned limitations we 586 
are working on the adaptation of the metabolic cycling technique for the use at 7 Tesla. 587 
Additionally, we are working on optimized coil designs to maximize SNR as successfully 588 
shown for the spinal cord (Hock et al., 2016). 589 
 590 
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Conclusion 591 
Conceptualized as a feasibility study, this 1H-MRS investigation provides first evidence of 592 
neurochemical alterations in the human TBSNC during experimental orofacial pain. Yet, the 593 
findings need to be cautiously interpreted, replication as well as expanding the research focus 594 
is indispensable.  595 
We would like to note that the application of 1H-MRS at the level of the TBSNC is possible, 596 
allowing the study of neurochemical compositions also in other brainstem subareas. Important 597 
in this regard is the measurement quality of tNAA, GABA and the six other quantified 598 
neurochemicals (table 1 and 2). Important, since we think that orofacial pain is mediated not 599 
only by tNAA and GABA. We rather hypothesize that the general neurochemical composition 600 
is somehow involved to code all complex intertwined facets of the human neural pain circuits. 601 
This has to be explored in following studies.  602 
This study provides first indications of human brainstem neurochemical nociceptive 603 
mechanisms. Hence, it complements identified neurochemical aberrations in animal models of 604 
acute/chronic orofacial pain. Thus, bridging both research fields might be in reach and offers 605 
hope for successful new treatment opportunities.  606 
 607 
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